Adam Zdeněk, Brančiková Dagmar, Romanová Gabriela, Pour Luděk, Krejčí Marta, König Jiří, Nebeský Tomáš, Adamová Zuzana, Štork Martin, Krejčí Martin, Ševčíková Sabina, Eid Michal, Král Zdeněk
Vnitr Lek. 2021 Winter;67(6):339-344.
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. Patients with HHT may have telangiectasias and later may develop arteriovenous malformations in various organs. Pacients suffer from many complications caused by the malformations and therefore by patients with HHT must by performed screening of this arteriovenous malformations. Optimal treatment of this malformations is best delivered throught a multidisciplinary approach. Farmacological treatment is described in next paper.
遗传性出血性毛细血管扩张症（HHT），也称为奥斯勒-韦伯-伦杜综合征，是一种常染色体显性疾病，可导致血管形成异常。HHT患者可能有毛细血管扩张，随后可能在各个器官中发展为动静脉畸形。患者会因这些畸形而出现许多并发症，因此必须对HHT患者进行这种动静脉畸形的筛查。这种畸形的最佳治疗方法最好通过多学科方法来提供。下一篇论文将描述药物治疗。
